Search results for "Derivatives"

showing 10 items of 432 documents

Convergence of a high-order compact finite difference scheme for a nonlinear Black-Scholes equation

2004

A high-order compact finite difference scheme for a fully nonlinear parabolic differential equation is analyzed. The equation arises in the modeling of option prices in financial markets with transaction costs. It is shown that the finite difference solution converges locally uniformly to the unique viscosity solution of the continuous equation. The proof is based on a careful study of the discretization matrices and on an abstract convergence result due to Barles and Souganides.

Nonlinear systemDiscretizationDifferential equationConvergence (routing)Finite differenceCompact finite differenceApplied mathematicsBlack–Scholes modelViscosity solutionHigh-order compact finite differences numerical convergence viscosity solution financial derivativesMathematics
researchProduct

ChemInform Abstract: Dimethylpyridin-4-ylamine-Catalyzed Alcoholysis of 2-Amino-N,N,N-trimethyl-9H-purin-6-ylammonium Chloride: An Effective Route to…

2010

NucleophileChemistrymedicineGuanine derivativesPurine derivativeOrganic chemistryGeneral MedicineChlorideCatalysismedicine.drugChemInform
researchProduct

A mechanical picture of fractional-order Darcy equation

2015

Abstract In this paper the authors show that fractional-order force-flux relations are obtained considering the flux of a viscous fluid across an elastic porous media. Indeed the one-dimensional fluid mass transport in an unbounded porous media with power-law variation of geometrical and physical properties yields a fractional-order relation among the ingoing flux and the applied pressure to the control section. As a power-law decay of the physical properties from the control section is considered, then the flux is related to a Caputo fractional derivative of the pressure of order 0 ⩽ β ≤ 1 . If, instead, the physical properties of the media show a power-law increase from the control sectio…

Numerical AnalysisAnomalous diffusionApplied MathematicsVolumetric fluxMass flowAnomalous diffusion; Anomalous scaling; Darcy equation; Fractional derivatives; Porous mediaMathematical analysisPorous mediaAnomalous diffusionFluxFractional derivativeViscous liquidDarcy–Weisbach equationFractional calculusModeling and SimulationDarcy equationSettore ICAR/08 - Scienza Delle CostruzioniPorous mediumAnomalous scalingMathematicsCommunications in Nonlinear Science and Numerical Simulation
researchProduct

Conformational properties of N′,N′-dimethylamides of N-acetyldehydroalanine and N-acetyl-(Z)-dehydrophenylalanine

2001

Conformational preferences of Ac-deltaAla-NMe2 and Ac-(Z)-deltaPhe-NMe2 were studied and compared with those of their monomethyl counterparts as well as with those of their saturated analogues. X-Ray data and energy calculations revealed a highly conservative conformation of the dehydro dimethylamides, which is located in a high-energy region of the Ramachandran map.

N¢-dimethylamidesaalanine and phenylalaninederivativesb-dehydroamino acidsGeneral Biochemistry Genetics and Molecular BiologyX-ray crystallographytheoretical calculations
researchProduct

SYNTHESIS OF NEW OLIGOPEPTIDE PYRROLE DERIVATIVES

2008

OLIGOPEPTIDE PYRROLE DERIVATIVESSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Synthesis of the new oligopeptide pyrrole derivative isonetropsin and its one pyrrole unit analogue

2013

We have designed and synthesized isonetropsin and its one pyrrole unit analogue in which the amine and carbonyl groups have been switched in positions 2 and 4, respectively instead of 4 and 2 positions of the natural antibiotic netropsin.

OligopeptideStereochemistryOrganic ChemistryNetropsinBiochemistryPyrrole derivativesDNA minor groove binderchemistry.chemical_compoundDNA minor groove binderschemistryNetropsinmental disordersDrug DiscoveryNetropsin; DNA minor groove binders; Isonetropsin; Oligopeptide pyrroleAmine gas treatingOligopeptide pyrrolepsychological phenomena and processesIsonetropsinPyrroleTetrahedron
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Cuticular hydrocarbon profiles in Blattella germanica: effects of halofenozide, boric acid and benfuracarb

2006

1379-1176 (Print) Journal Article; In order to complete previous studies conducted on Blattella germanica, three insecticides from different groups were evaluated: boric acid, an inorganic compound, benfuracarb, a carbamate, and halofenozide, a non-steroidal ecdysone agonist. Boric acid (8.20%, LD50) and benfuracarb (2%, LD50) were incorporated into the diet and orally administrated to newly emerged adults of both sexes, while halofenozide (0.33%, LD50) was applied topically. Hydrocarbons extracts was made on bidistilled pentane from control and treated series sampled 6 days following treatment. Extracts was analyzed by gas chromatography. Data showed that cuticular profiles of control and …

OralMaleChromatographyHydrazines/*toxicityTime Factorsintegumentary systembeta-Alanine/*analogs & derivatives/toxicityHydrocarbons/*analysisBenzofurans/*toxicityBenzoic Acids/*toxicityLethal Dose 50TopicalInsecticides/*toxicityBoric Acids/*toxicityGasAdministrationAnimalsFemaleBlattellidae/chemistry/drug effects/growth & development
researchProduct